Exhaled nitric oxide correlates with airway hyperresponsiveness in steroid-naive patients with mild asthma.
Endogenously released nitric oxide (NO) has been detected in the exhaled air of humans. Exhaled NO (NOexh) levels have been significantly increased in patients with inflammatory airways disorders such as asthma, and NOexh has been suggested to be a usable marker of airway inflammation. In the present study, NOexh levels were measured both in steroid-treated and untreated subjects with mild asthma, and were correlated with the degree of airway hyperresponsiveness (AHR), measured as the dose of histamine that produced a 20% decrease in FEV1 (PC20histamine). NOexh levels, which were significantly increased in steroid-naive patients (Group A1: NOexh = 21 +/- 11 ppb; n = 56) in comparison with levels in control subjects (Group B: NOexh = 10 +/- 2 ppb; n = 20; p < 0.001), correlated significantly with the PC20histamine (r = -0.65; p < 0.0001). The NOexh level was significantly lower in patients with chronic cough of other causes than bronchial asthma (Group A2: NOexh = 11 +/- 3 ppb; n = 18) when compared with the level in subjects with mild asthma (Group A1: p < 0.001). Therefore, the noninvasive measurement of NOexh allowed us to discriminate, among patients with respiratory complaints, between those with and without AHR. In asthmatic subjects treated with inhaled steroids, the NOexh levels were significantly lower (Group A3: NOexh = 13 +/- 5 ppb; n = 25) than in untreated subjects (Group A1; p < 0.01), and there was no relationship with the PC20histamine (r = -0.18, p = NS). These findings confirm that NOexh reflects AHR in patients with mild asthma who have not already been treated with inhaled steroids. Patients treated with inhaled steroids had an NOexh level comparable to levels in control subjects, although AHR could still be demonstrated.
Dupont
L J
LJ
Department of Pulmonary Medicine, University Hospital Gasthuisberg, Katholieke Universiteit Leuven, Belgium.
Rochette
F
F
Demedts
M G
MG
Verleden
G M
GM
D000318:Adrenergic beta-Agonists / Q000008:administration & dosage / Q000627:therapeutic use; D000328:Adult; D000402:Airway Obstruction / Q000378:metabolism / Q000503:physiopathology; D018927:Anti-Asthmatic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000627:therapeutic use; D001249:Asthma / Q000188:drug therapy / Q000378:metabolism* / Q000503:physiopathology; D001507:Beclomethasone / Q000008:administration & dosage / Q000627:therapeutic use; D015415:Biomarkers / Q000032:analysis; D016535:Bronchial Hyperreactivity / Q000378:metabolism* / Q000503:physiopathology; D001985:Bronchial Provocation Tests; D002908:Chronic Disease; D003371:Cough / Q000378:metabolism / Q000503:physiopathology; D004417:Dyspnea / Q000378:metabolism / Q000503:physiopathology; D005260:Female; D005541:Forced Expiratory Volume / Q000187:drug effects; D005938:Glucocorticoids / Q000008:administration & dosage / Q000627:therapeutic use; D006632:Histamine / Q000008:administration & dosage; D006801:Humans; D008297:Male; D009569:Nitric Oxide / Q000032:analysis / Q000378:metabolism*; D012119:Respiration; D012135:Respiratory Sounds / Q000502:physiology
D000318:Adrenergic beta-Agonists; D018927:Anti-Asthmatic Agents; D000893:Anti-Inflammatory Agents; D015415:Biomarkers; D005938:Glucocorticoids; D009569:Nitric Oxide; D006632:Histamine; D001507:Beclomethasone